Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
| ▸ | GBA1 | P04062 | 1/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10396809 | 0.81 | HRH4 (0.56) | HRH4HRH3SMN1; SMN2 | |
| SCHEMBL23330166 | 0.81 | NCF1 (0.52) | HRH4HRH3GBA1NCF1MAP4K4 | |
| SCHEMBL7774440 | 0.80 | HRH4 (0.55) | HRH4HRH3MAP4K4CKS1BSKP1 | |
| Hydrochloric Acid SCHEMBL10396594 | 0.80 | HRH4 (0.55) | HRH4HRH3SMN1; SMN2 | |
| SCHEMBL30488018 | 0.78 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL2169898 | 0.78 | HRH4 (1.00) | HRH4HRH3 | |
| SCHEMBL5889086 | 0.78 | MAP4K4 (0.54) | GBA1NCF1MAP4K4CASP6GFER | |
| SCHEMBL10678810 | 0.76 | HRH4 (0.70) | HRH4HRH3CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL30296862 | 0.76 | HRH4 (0.70) | HRH4HRH3CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL25897198 | 0.76 | HRH4 (0.45) | HRH4GBA1NCF1MAP4K4CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1673092-B1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA IP NV (BE) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | HRH4 294/4885HRH3 631/4885GBA1 3862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.